Evidence map›Paper›PMID 37818824›Full record

ArticleEMBO reports2023

Tetracyclines activate mitoribosome quality control and reduce ER stress to promote cell survival.

Conor T Ronayne, Thomas D Jackson, Christopher F Bennett, Elizabeth A Perry, Noa Kantorovic, Pere Puigserver

Open access · greenAbstract read
In one paragraph

Article in EMBO reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Conor T RonayneDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0002-9591-327X
Thomas D JacksonDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0002-4864-496X
Christopher F BennettDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0003-1927-0732
Elizabeth A PerryDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0001-9506-2578
Noa KantorovicDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
Pere PuigserverDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0002-0884-2718
Harvard University · US

Funding

Metabolic Vulnerabilities in Melanoma TumorsR01CA181217 · NCI · DANA-FARBER CANCER INST · PI PUIGSERVER, PERE · 2014 to 2024
$3.7M
Cancer Chemical Biology and Metabolism Training ProgramT32CA236754 · NCI · DANA-FARBER CANCER INST · PI Nika N Danial, THOMAS M ROBERTS · 2019 to 2026
$2.6M
Mitochondrial Protein Translation Signaling and Survival MechanismsR56AG074527 · NIA · DANA-FARBER CANCER INST · PI PUIGSERVER, PERE · 2021 to 2021
$338k
Chemical Approaches to Rescue Human Mitochondrial Disease MutationsF30DE028206 · NIDCR · HARVARD MEDICAL SCHOOL · PI PERRY, ELIZABETH AGUILAR · 2018 to 2022
$190k
Characterization of genetic modifiers of bioenergetic rescue in mitochondrial disease cell linesF32GM125243 · NIGMS · DANA-FARBER CANCER INST · PI BENNETT, CHRISTOPHER F. · 2017 to 2020
$188k
NCI NIH HHS R01 CA181217NCI NIH HHS T32 CA236754NIA NIH HHS R56 AG074527NIDCR NIH HHS F30 DE028206NIGMS NIH HHS F32 GM125243
6 · The paper itself

Abstract

Mitochondrial diseases are a group of disorders defined by defects in oxidative phosphorylation caused by nuclear- or mitochondrial-encoded gene mutations. A main cellular phenotype of mitochondrial disease mutations is redox imbalances and inflammatory signaling underlying pathogenic signatures of these patients. One method to rescue this cell death vulnerability is the inhibition of mitochondrial translation using tetracyclines. However, the mechanisms whereby tetracyclines promote cell survival are unknown. Here, we show that tetracyclines inhibit the mitochondrial ribosome and promote survival through suppression of endoplasmic reticulum (ER) stress. Tetracyclines increase mitochondrial levels of the mitoribosome quality control factor MALSU1 (Mitochondrial Assembly of Ribosomal Large Subunit 1) and promote its recruitment to the mitoribosome large subunit, where MALSU1 is necessary for tetracycline-induced survival and suppression of ER stress. Glucose starvation induces ER stress to activate the unfolded protein response and IRE1α-mediated cell death that is inhibited by tetracyclines. These studies establish a new interorganelle communication whereby inhibition of the mitoribosome signals to the ER to promote survival, implicating basic mechanisms of cell survival and treatment of mitochondrial diseases.

Indexed as

Mitochondrial DiseasesMitochondrial RibosomesCell SurvivalEndoplasmic Reticulum StressEndoribonucleasesHumansProtein Serine-Threonine KinasesTetracyclinesEndoribonucleasesProtein Serine-Threonine KinasesTetracyclinesIRE1αMALSU1mitochondrial diseasemitoribosometetracyclines

Identifiers

PMID37818824
PMCPMC10702820
OpenAlexW4387562864

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.